What is Celula?
Celula specializes in integrated diagnostic solutions, with a strategic focus on advancing prenatal testing and enhancing the accuracy of women's diagnostics, particularly in the early detection of ovarian cancer. The company also actively engages in research and development partnerships to drive innovation within the diagnostics field. Celula serves healthcare providers and researchers seeking cutting-edge diagnostic tools, positioning itself as a key player in improving health outcomes through advanced technology.
How much funding has Celula raised?
Celula has raised a total of $10M across 1 funding round:
Debt
$10M
Debt (2015): $10M with participation from Oxford Finance
Key Investors in Celula
Oxford Finance
Oxford Finance, founded in 2002 and headquartered in Alexandria, Virginia, is a specialty finance firm that offers flexible financial solutions to healthcare and life sciences companies worldwide. Their involvement suggests a focus on supporting established companies with debt financing for growth and operations.
What's next for Celula?
The recent major strategic investment, coupled with the overall enterprise-level funding, suggests Celula is poised for significant scaling and further product development. This capital infusion will likely accelerate their efforts in refining prenatal testing technologies and expanding their cancer detection capabilities, especially for ovarian cancer. Future initiatives may involve broader market penetration, strategic partnerships with larger healthcare institutions, and continued investment in R&D to maintain a competitive edge in the rapidly evolving diagnostics landscape.
See full Celula company page
